Loading
A phase 3 trial of Romiplostim in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer is a phase 3 interventional study registered as NCT03937154 by Amgen, with 145 participants enrolled, started 2020-02-26 and due to reach its primary completion in 2026-03-10. Interventions recorded: Romiplostim and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amgen, Non-small-cell lung cancer and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Amgen, Non-small-cell lung cancer and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/